Liewei Wang

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies
    Thomas C Wood
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Biol Chem 281:7364-73. 2006
  2. pmc Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression
    Liang Li
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 68:7050-8. 2008
  3. pmc Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma
    Katarzyna A Ellsworth
    Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 8:e70216. 2013
  4. pmc FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer
    Junmei Hou
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e36252. 2012
  5. pmc Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers
    Liang Li
    Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 4:e7765. 2009
  6. pmc The role of FKBP5 in cancer aetiology and chemoresistance
    L Li
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Cancer 104:19-23. 2011
  7. pmc Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines
    Liang Li
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    BMC Genomics 15:93. 2014
  8. ncbi request reprint Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions
    L Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Oncogene 25:1629-38. 2006
  9. pmc FKBP51 regulation of AKT/protein kinase B phosphorylation
    Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, MN, USA
    Curr Opin Pharmacol 11:360-4. 2011
  10. pmc Human 3beta-hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Steroid Biochem Mol Biol 107:88-99. 2007

Research Grants

Collaborators

Detail Information

Publications60

  1. ncbi request reprint Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies
    Thomas C Wood
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Biol Chem 281:7364-73. 2006
    ..These results raise the possibility that inherited variation in AS3MT may contribute to variation in arsenic metabolism and, perhaps, arsenic-dependent carcinogenesis in humans...
  2. pmc Gemcitabine and cytosine arabinoside cytotoxicity: association with lymphoblastoid cell expression
    Liang Li
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 68:7050-8. 2008
    ..Our results suggest that cell-based model system studies, when combined with complementary functional characterization, may help to identify biomarkers for response to chemotherapy with these cytidine analogues...
  3. pmc Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma
    Katarzyna A Ellsworth
    Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 8:e70216. 2013
    ..Genetic variation in FKBP5 could influence its function and, ultimately, treatment response of pancreatic cancer...
  4. pmc FKBP5 as a selection biomarker for gemcitabine and Akt inhibitors in treatment of pancreatic cancer
    Junmei Hou
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e36252. 2012
    ..These results provide evidence in support of future clinical trials designed to tailor therapy based on our observations...
  5. pmc Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers
    Liang Li
    Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA
    PLoS ONE 4:e7765. 2009
    ....
  6. pmc The role of FKBP5 in cancer aetiology and chemoresistance
    L Li
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Br J Cancer 104:19-23. 2011
    ..In this review, we will focus on the recently discovered role of FKBP5 in cancer aetiology and response to antineoplastic therapy...
  7. pmc Discovery of genetic biomarkers contributing to variation in drug response of cytidine analogues using human lymphoblastoid cell lines
    Liang Li
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, USA
    BMC Genomics 15:93. 2014
    ..3 million SNPs and 54,000 basal expression probesets to perform genome-wide association studies (GWAS) with gemcitabine and AraC IC50 values...
  8. ncbi request reprint Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions
    L Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Oncogene 25:1629-38. 2006
    ....
  9. pmc FKBP51 regulation of AKT/protein kinase B phosphorylation
    Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Rochester, MN, USA
    Curr Opin Pharmacol 11:360-4. 2011
    ..In this review, we will focus on the function of FKBP51 as a scaffolding protein in the regulation of AKT activation and, in turn, its role in tumorigenesis and response to chemotherapy...
  10. pmc Human 3beta-hydroxysteroid dehydrogenase types 1 and 2: Gene sequence variation and functional genomics
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN 55905, USA
    J Steroid Biochem Mol Biol 107:88-99. 2007
    ..In aggregate, these results provide a basis for study of the possible role in human disease of common genetic variation in HSD3B1 and HSD3B2...
  11. pmc Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 70:319-28. 2010
    ..Our findings indicate that two common genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to aromatase inhibitors...
  12. pmc Pharmacogenomics: a systems approach
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Wiley Interdiscip Rev Syst Biol Med 2:3-22. 2010
    ....
  13. pmc Proteasome beta subunit pharmacogenomics: gene resequencing and functional genomics
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA
    Clin Cancer Res 14:3503-13. 2008
    ..Genetic variation in proteasome subunits could influence both proteasome function and response to drug therapy...
  14. ncbi request reprint Human aromatase: gene resequencing and functional genomics
    Cynthia X Ma
    Department of Medical Oncology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer Res 65:11071-82. 2005
    ..These observations indicate that genetic variation in CYP19 might contribute to variation in the pathophysiology of estrogen-dependent disease...
  15. ncbi request reprint Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics
    Yuan Ji
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    J Neurochem 95:1766-76. 2005
    ..These observations raise the possibility of inherited variation in the ability to form epinephrine from norepinephrine as a result of variant PNMT polymorphisms and haplotypes...
  16. pmc Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics
    Pinar Aksoy
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 19:567-76. 2009
    ..One gene that was significantly associated with gemcitabine cytotoxicity was a nucleotidase family member, NT5C3. Very little is known with regard to the pharmacogenomics of this family of enzymes...
  17. pmc Human glucocorticoid receptor alpha gene (NR3C1) pharmacogenomics: gene resequencing and functional genomics
    Nifang Niu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Clin Endocrinol Metab 94:3072-84. 2009
    ..There are large variations in both physiological and therapeutic response to glucocorticoids. Multiple previous studies suggested that genetic polymorphisms in GRalpha (NR3C1) might play an important role...
  18. pmc Genetic association with overall survival of taxane-treated lung cancer patients - a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study
    Nifang Niu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    BMC Cancer 12:422. 2012
    ....
  19. pmc Gene set analysis of purine and pyrimidine antimetabolites cancer therapies
    Brooke L Fridley
    Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 21:701-12. 2011
    ..Application of such methods to pharmacogenomic studies may enable the detection of more subtle effects of multiple genes in the same pathway that may be missed by assessing each gene individually...
  20. pmc Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation
    Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Proc Natl Acad Sci U S A 102:9394-9. 2005
    ..The results of these experiments provide insight into a unique pharmacogenetic mechanism by which common polymorphisms affect TPMT protein function and, as a result, therapeutic response to thiopurine drugs...
  21. pmc TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Mol Endocrinol 27:657-70. 2013
    ..TSPYL5 induced CYP19A1 expression and that of many other genes. These studies have revealed a novel mechanism for regulating aromatase expression and plasma E2 concentrations in postmenopausal women with ER(+) breast cancer...
  22. pmc FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder
    Katarzyna A Ellsworth
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 23:156-66. 2013
    ....
  23. pmc Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer
    Liang Li
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 22:105-16. 2012
    ....
  24. pmc FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt
    Huadong Pei
    Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Cell 16:259-66. 2009
    ..Overall, our findings identify FKBP51 as a negative regulator of the Akt pathway, with potentially important implications for cancer etiology and response to chemotherapy...
  25. ncbi request reprint Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics
    Oreste E Salavaggione
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine Mayo Clinic, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 15:801-15. 2005
    ..These studies indicate that a common mechanism responsible for alterations in the activity of variant TPMT allozymes involves alteration in the level of enzyme protein due, at least in part, to accelerated degradation...
  26. pmc Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy
    Xiang Lin Tan
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Clin Cancer Res 17:5801-11. 2011
    ....
  27. ncbi request reprint Canine red blood cell thiopurine S-methyltransferase: companion animal pharmacogenetics
    Oreste E Salavaggione
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    Pharmacogenetics 12:713-24. 2002
    ..These observations represent a step towards the application of pharmacogenetic and pharmacogenomic principles to companion animal drug therapy...
  28. pmc Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines
    Nifang Niu
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota 55905, USA
    Genome Res 20:1482-92. 2010
    ..Studies performed with LCLs can help to identify novel biomarkers that might contribute to variation in response to radiation therapy and enhance our understanding of mechanisms underlying that variation...
  29. ncbi request reprint Aggresome formation and pharmacogenetics: sulfotransferase 1A3 as a model system
    Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Biochem Biophys Res Commun 325:426-33. 2004
    ..The possible role of aggresome formation in pharmacogenetics should be evaluated in naturally occurring systems with inherited alteration in encoded amino acid sequence...
  30. pmc Mycophenolic acid response biomarkers: a cell line model system-based genome-wide screen
    Tse Yu Wu
    Division of Clinical Pharmacology, Department of Pharmacology and Experimental Therapeutics, Rochester, MN 55905, USA
    Int Immunopharmacol 11:1057-64. 2011
    ..These studies have identified novel candidate genes that may contribute to variation in response to MPA therapy and, as a result, may help make it possible to move toward more highly individualized MPA-based immunosuppressive therapy...
  31. pmc Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors
    James N Ingle
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 28:4674-82. 2010
    ....
  32. pmc Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity
    Fang Li
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Drug Metab Dispos 38:2329-38. 2010
    ..4 × 10(-10), R = -0.376). The thiopurine cellular circulation and genetic polymorphisms for genes encoding the proteins involved should be incorporated into future studies of thiopurine drug therapy and effect...
  33. pmc Identifying the genetic variation of gene expression using gene sets: application of novel gene Set eQTL approach to PharmGKB and KEGG
    Ryan Abo
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, United States of America
    PLoS ONE 7:e43301. 2012
    ..Our proposed GS-eQTL method effectively addresses the multiple testing limitations in eQTL studies and provides biological context for SNP-expression associations...
  34. pmc Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression
    Mohan Liu
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Breast Cancer Res 14:R41. 2012
    ..In the present study, we set out to determine whether these SNPs might influence cytokine expression and effect more widely, and, if so, to explore the mechanism of TCL1A-related AI-induced side effects...
  35. pmc Copy number variation and cytidine analogue cytotoxicity: a genome-wide association approach
    Krishna R Kalari
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    BMC Genomics 11:357. 2010
    ..In the present study, we set out to test the hypothesis that variation in copy number might contribute to variation in cytidine analogue response phenotypes...
  36. pmc A Bayesian integrative genomic model for pathway analysis of complex traits
    Brooke L Fridley
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Genet Epidemiol 36:352-9. 2012
    ..Further research is required to extend and modify this integrative modeling framework to increase computational efficiency to best capitalize on the wealth of information available across multiple genomic data types...
  37. pmc Use of the gamma method for self-contained gene-set analysis of SNP data
    Joanna M Biernacka
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Hum Genet 20:565-71. 2012
    ..We also applied all of the considered GSA methods to data from a pharmacogenomic study of cisplatin, and obtained evidence suggesting that the glutathione metabolism GS is associated with cisplatin drug response...
  38. pmc A Bayesian hierarchical nonlinear model for assessing the association between genetic variation and drug cytotoxicity
    Brooke L Fridley
    Department of Health Sciences Research, Harwick 766, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Stat Med 28:2709-22. 2009
    ....
  39. pmc Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention
    James N Ingle
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Cancer Discov 3:812-25. 2013
    ..ZNF423 appeared to be an estrogen-inducible BRCA1 transcription factor. The OR for differences in breast cancer risk during SERM therapy for subjects homozygous for both protective or both risk alleles for ZNF423 and CTSO was 5.71. ..
  40. pmc Thiopurine pharmacogenomics: association of SNPs with clinical response and functional validation of candidate genes
    Alice Matimba
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN 55905, USA
    Pharmacogenomics 15:433-47. 2014
    ..We investigated candidate genes associated with thiopurine metabolism and clinical response in childhood acute lymphoblastic leukemia...
  41. pmc MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
    Huadong Pei
    Division of Oncology Research, Mayo Clinic, Rochester, Minnesota 55905, USA
    Nature 470:124-8. 2011
    ..Thus, we propose that a pathway involving γH2AX-MDC1-MMSET regulates the induction of H4K20 methylation on histones around DSBs, which, in turn, facilitates 53BP1 recruitment...
  42. ncbi request reprint Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation
    Liewei Wang
    Departments of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School Mayo Clinic Mayo Foundation, Rochester, Minnesota 55905, USA
    Pharmacogenetics 13:555-64. 2003
    ..Therefore, chaperone proteins play an important mechanistic role in this clinically significant example of pharmacogenetic variation in drug metabolism...
  43. pmc Testing whether genetic variation explains correlation of quantitative measures of gene expression, and application to genetic network analysis
    Zhaoxia Yu
    Division of Biostatistics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA
    Stat Med 27:3847-67. 2008
    ..These methods can be used to assist the interpretation of regulation of gene expression and the construction of gene regulatory networks...
  44. ncbi request reprint Human histamine N-methyltransferase pharmacogenetics: gene resequencing, promoter characterization, and functional studies of a common 5'-flanking region single nucleotide polymorphism (SNP)
    Liewei Wang
    Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Graduate School Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Biochem Pharmacol 64:699-710. 2002
    ..These results represent an additional step in the definition of molecular genetic mechanisms involved in the regulation of this important autacoid-metabolizing enzyme in humans...
  45. ncbi request reprint Pharmacogenomics: bench to bedside
    Richard Weinshilboum
    Mayo Medical School Mayo Graduate School, Mayo Clinic College of Medicine, Department of Molecular Pharmacology and Experimental Therapeutics, Rochester, Minnesota 55905, USA
    Nat Rev Drug Discov 3:739-48. 2004
    ....
  46. pmc Localization of association signal from risk and protective variants in sequencing studies
    Abra Brisbin
    Department of Health Sciences Research, Mayo Clinic Rochester, MN, USA
    Front Genet 3:173. 2012
    ..The application of the sliding-window test procedure detected an association in a sub-region spanning an exon and two introns, when rare and common variants were analyzed together...
  47. pmc Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms
    Yuan Ji
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Res 68:5997-6005. 2008
    ....
  48. pmc Pharmacogenomics: candidate gene identification, functional validation and mechanisms
    Liewei Wang
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics and Medicine, Mayo Medical School Mayo Clinic, Rochester, MN 55905, USA
    Hum Mol Genet 17:R174-9. 2008
    ....
  49. pmc Thiopurine S-methyltransferase pharmacogenetics: autophagy as a mechanism for variant allozyme degradation
    Fang Li
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic Mayo Medical School, Rochester, Minnesota 55905, USA
    Pharmacogenet Genomics 18:1083-94. 2008
    ..It also forms aggresomes, suggesting a possible dynamic balance between degradation and aggregation. We set out to identify genes encoding proteins participating in these processes...
  50. ncbi request reprint Candidate-gene association studies with pedigree data: controlling for environmental covariates
    S L Slager
    Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905 USA
    Genet Epidemiol 24:273-83. 2003
    ..We also find GEE to fail at least 5% of the time for each simulation configuration; at times, the failure rate reaches above 80%. In summary, our robust method may be the only current regression analysis method available for MCC data...
  51. ncbi request reprint Pharmacogenetics and pharmacogenomics: development, science, and translation
    Richard M Weinshilboum
    Division of Clinical Pharmacology, Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic College of Medicine, Mayo Medical School Mayo Foundation, Rochester, Minnesota 55905, USA
    Annu Rev Genomics Hum Genet 7:223-45. 2006
    ..However, significant challenges remain to be overcome if pharmacogenetics-pharmacogenomics is to achieve its full potential as a major medical application of genomic science...
  52. ncbi request reprint Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity
    Richard Weinshilboum
    Department of Molecular Pharmacology and Experimental Therapeutics and Medicine, Mayo Medical School Mayo Clinic Mayo Foundation, Rochester, MN 55905, USA
    Clin Pharmacol Ther 75:253-8. 2004
  53. pmc Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol
    Suzette J Bielinski
    Department of Health Sciences Research, Mayo Clinic, Rochester, MN Electronic address
    Mayo Clin Proc 89:25-33. 2014
    ....
  54. pmc Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy
    Yafei Li
    Department of Health Sciences Research, Rochester, Minnesota, USA
    Clin Cancer Res 17:3830-40. 2011
    ....
  55. pmc Sumoylation of MDC1 is important for proper DNA damage response
    Kuntian Luo
    Key Laboratory of Arrhythmia, Ministry of Education, East Hospital, Tongji University School of Medicine, Shanghai, China
    EMBO J 31:3008-19. 2012
    ..These results reveal the intricate dynamics governing the assembly and disassembly of DNA damage factors at sites of DNA damage for prompt response to DNA damage...
  56. ncbi request reprint The APC E1317Q variant in adenomatous polyps and colorectal cancers
    D Hahnloser
    Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer Epidemiol Biomarkers Prev 12:1023-8. 2003
    ..These results underscore the importance of carefully defining the controls to be used in comparisons of allele frequencies...
  57. ncbi request reprint Role of HPC2/ELAC2 in hereditary prostate cancer
    L Wang
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 61:6494-9. 2001
    ..Cumulatively, these results suggest that alterations within the HPC2/ELAC2 gene play a limited role in genetic susceptibility to HPC...
  58. ncbi request reprint Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells
    H Huang
    Department of Laboratory Medicine and Pathology, Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 59:2981-8. 1999
    ..Our data demonstrate that the histone hyperacetylation signaling pathway is activated during NaBu-mediated differentiation of PC-3 cells, and the new gene, CPA3, is involved in this pathway...
  59. ncbi request reprint Identification and characterization of a novel androgen receptor coregulator ARA267-alpha in prostate cancer cells
    X Wang
    George Whipple Laboratory for Cancer Research, Department of Urology, University of Rochester, Rochester, New York 14642, USA
    J Biol Chem 276:40417-23. 2001
    ..Together, our data demonstrate that ARA267-alpha is a new AR coregulator containing the SET domain with an exceptionally large molecular mass that can enhance AR transactivation in prostate cancer cells...

Research Grants3